{"schema_version":"secwatch.filing_event.v1","accession":"0000320017-22-000046","form_type":"8-K","ticker":"LSTA","cik":"0000320017","company_name":"LISATA THERAPEUTICS, INC.","filed_at":"2022-05-23T23:59:59+00:00","discovered_at":"2026-05-14T18:04:03.197465+00:00","generated_at":"2026-06-25T08:24:18.353091+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Caladrius suspends enrollment in Phase 2b FREEDOM Trial of XOWNA; interim analysis expected Aug 2022","bullets":["Enrollment paused in 105-patient double-blind placebo-controlled FREEDOM Trial; only ~35 patients enrolled to date.","Interim analysis of first 20+ patients with 6-month follow-up data to evaluate efficacy/safety and effect size.","Results due August 2022; next development steps for XOWNA to be announced by year-end 2022.","Causes: COVID-19, supply shortages of catheters/contrast agent, and discontinuation of specified diagnostic equipment.","CEO cites alternative development plan needed; prior timeline of >4 years to complete deemed not viable."],"urls":{"canonical":"https://secwatch.observer/filing/0000320017-22-000046","json":"https://secwatch.observer/filing/0000320017-22-000046.json","markdown":"https://secwatch.observer/filing/0000320017-22-000046.md","text":"https://secwatch.observer/filing/0000320017-22-000046.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/320017/000032001722000046/0000320017-22-000046-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/320017/000032001722000046/clbs-20220523.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T08:24:18.353091+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}